Skip to main content
Smart Investors Daily
ICON Public Limited Company logo

NASDAQ · ICLR

ICON Public Limited Company

Healthcare · Medical - Diagnostics & Research

$195.16

Down-$4.80 (-2.46%)

Updated Nov 20, 2026, 1:45 AM

SID Score

7.4/10

Composite research score

Smart Money

56/100

Neutral

Market cap
14.49B
P/E ratio
24.5
Dividend yield
0.00%
52-week range
$66.57 – $219.04
Volume
548.49K
Avg. volume
993.9K

Price performance · ICLR

ICLR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

ICLR closed at $195.16 after 20 trading sessions, up 5.25% for the selected period.

Last close
$195.16
Period change
+5.25%
Period low
$182.98
Period high
$215.48
Daily close
View OHLC price history
ICLR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$193.75$198.11$192.105$195.16548.49K
Nov 17, 2026$191.24$197.47$190.435$195.02662.79K
Nov 16, 2026$195.47$196.32$188.55$191.40826.22K
Nov 13, 2026$200.56$200.56$194.39$194.65966.54K
Nov 12, 2026$198.43$200.75$194.06$200.51779.98K
Nov 11, 2026$204.32$208.38$199.41$199.70647.32K
Nov 10, 2026$206.30$206.30$200.8675$204.63617.11K
Nov 9, 2026$206.10$210.58$203.845$207.591.04M
Nov 6, 2026$200.87$208.26$200.535$204.741.38M
Nov 5, 2026$203.41$206.4299$197.21$201.651.48M
Nov 4, 2026$205.17$209.715$202.09$203.111.26M
Nov 3, 2026$204.45$209.735$203.06$203.771.1M
Nov 2, 2026$206.00$211.00$202.84$205.14778.52K
Oct 30, 2026$211.52$212.905$207.01$211.362.58M
Oct 29, 2026$211.53$219.04$207.535$215.481.8M
Oct 28, 2026$199.19$214.94$195.80$214.163.95M
Oct 27, 2026$182.23$186.99$181.735$182.98890.73K
Oct 26, 2026$182.08$185.59$179.16$183.781.07M
Oct 23, 2026$184.25$185.57$179.89$185.271.02M
Oct 22, 2026$180.09$190.56$180.09$185.431.02M

Latest ICLR news

The latest Smart Investors Daily articles mentioning ICLR.

ICLR research

Overview

Company profile and research snapshot.

Company profile

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$205.00
Implied upside
—
Analysts
24
ICLR recent ratings
DateFirmRatingTarget
Oct 29, 2026BairdOutperform—
Oct 29, 2026RBC CapitalOutperform—
Oct 29, 2026Truist SecuritiesBuy—
Oct 29, 2026BarclaysEqual-Weight—
Oct 29, 2026UBSNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.